Dear Pharmalucence Customer:

It is my pleasure to announce to you that Pharmalucence has been acquired by Sun Pharmaceuticals (, a world leader in the development and marketing of generic drugs.

Pharmalucence chose to join the Sun Pharma family of companies to accelerate our growth and diversification. Combining our advanced parenteral production capabilities and Nuclear Medicine product
line with Sun Pharma’s extensive experience, resources and global presence in generics will take Pharmalucence’s business development much further, in less time, than could have been achieved under our previous private ownership.

As a Pharmalucence customer, you will have no disruption from this ownership transition. Our people, our products and our business will continue to operate as in the past, but from within the larger Sun
Pharma company. Continued investment in our nuclear medicine business, including development of new products and expansion into international markets, is planned. In addition, expansion of Pharmalucence’s advanced drug production platform will be implemented, further enabling the
manufacture of existing and new injectable pharmaceuticals for the U.S. market.

There is one change in business plan related to our new ownership. With our integration into the larger Sun Pharma drug production network, Pharmalucence has fully subscribed its production capacity and will not seek additional Contract Production customers. Ongoing support of existing Contract Production customers will continue to be an important part of our business operations.

Thank you for your business and continued support. We look forward to the next phase in Pharmalucence’s development as a Sun Pharma company and our ongoing relationship with you. If you have any questions regarding this news, please don’t hesitate to contact us.


Glenn Alto Vice President and General Manager Pharmalucence Inc., a Sun Pharma company